Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Treasury Shares (2016 - 2025)

Agios Pharmaceuticals' Treasury Shares history spans 5 years, with the latest figure at $802.5 million for Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $802.5 million; the TTM value through Dec 2025 reached $802.5 million, changed 0.0%, while the annual FY2025 figure was $802.5 million, 0.0% changed from the prior year.
  • Treasury Shares reached $16.2 million in Q4 2025 per AGIO's latest filing, roughly flat from $16.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $16.2 billion in Q1 2022 to a low of $7.1 million in Q1 2021.
  • Average Treasury Shares over 5 years is $7.8 billion, with a median of $5.3 billion recorded in 2021.
  • The largest YoY upside for Treasury Shares was 51.69% in 2022 against a maximum downside of 0.0% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $802.5 million in 2021, then changed by 0.0% to $802.5 million in 2022, then changed by 0.0% to $802.5 million in 2023, then changed by 0.0% to $802.5 million in 2024, then changed by 0.0% to $802.5 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Treasury Shares are $802.5 million (Q4 2025), $802.5 million (Q3 2025), and $802.5 million (Q2 2025).